Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegol-Sihematide for Anemia in NDD-CKD
NCT03903809Phase 3Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2019
- Primary completion
- Oct 2021
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of peglmolesatide in anemia, sponsored by Hansoh Pharmaceutical Group. Status: unknown.
02
Drugs
peglmolesatide
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03903809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903809.